Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Medicine
Volume 2011, Article ID 710216, 2 pages
Case Report

Development of Nephrotic Syndrome after Administration of Sorafenib in a Case of Metastatic Renal Cell Carcinoma

Department of Urology, The University of Tokyo Hospital, Tokyo 113-8655, Japan

Received 7 July 2011; Accepted 9 August 2011

Academic Editor: W. Zidek

Copyright © 2011 Yumiko Okuno et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [7 citations]

The following is the list of published articles that have cited the current article.

  • Tasuku Nagasawa, Md Abdul Hye Khan, and John D. Imig, “Captopril attenuates hypertension and renal injury induced by the vascular endothelial growth factor inhibitor sorafenib,” Clinical And Experimental Pharmacology And Physiology, vol. 39, no. 5, pp. 454–461, 2012. View at Publisher · View at Google Scholar
  • Nedim Turan, Selcuk Cemil Ozturk, Salih Inal, Galip Guz, Mustafa Benekli, Leyla Memis, Bulent Cetin, and Suleyman Buyukberber, “Sunitinib-and sorafenib-induced nephrotic syndrome in a patient with gastrointestinal stromal tumor,” Annals of Pharmacotherapy, vol. 46, no. 10, pp. e27–e27, 2012. View at Publisher · View at Google Scholar
  • Eric Wallace, William Lyndon, Phillip Chumley, Edgar A. Jaimes, and Huma Fatima, “Dasatinib-Induced Nephrotic-Range Proteinuria,” American Journal of Kidney Diseases, vol. 61, no. 6, pp. 1026–1031, 2013. View at Publisher · View at Google Scholar
  • Mario Ollero, and Djillali Sahali, “Inhibition of the VEGF signalling pathway and glomerular disorders,” Nephrology Dialysis Transplantation, vol. 30, no. 9, pp. 1449–1455, 2015. View at Publisher · View at Google Scholar
  • Hai-Liang Zhang, Xiao-Jian Qin, Hong-Kai Wang, Wei-Jie Gu, Chun-Guang Ma, Guo-Hai Shi, Liang-Ping Zhou, and Ding-Wei Ye, “Clinicopathological and prognostic factors for long-term survival in Chinese patients with metastatic renal cell carcinoma treated with sorafenib: A single-center retrospective study,” Oncotarget, vol. 6, no. 34, pp. 36870–36883, 2015. View at Publisher · View at Google Scholar
  • Josiah D. Land, Adrienne H. Chen, Bradley J. Atkinson, Diana H. Cauley, and Nizar M. Tannir, “Proteinuria with first-line therapy of metastatic renal cell cancer,” Journal Of Oncology Pharmacy Practice, vol. 22, no. 2, pp. 235–241, 2016. View at Publisher · View at Google Scholar
  • Satoru Nihei, Junya Sato, Toshiyuki Harada, Shoichi Kuyama, Toshiro Suzuki, Nobutsugu Waga, Yoshitaka Saito, Shigeki Kisara, Atsuko Yokota, Kouji Okada, Masami Tsuchiya, Kazufumi Terui, Yumiko Tadokoro, Takeshi Chiba, Kenzo Kudo, Satoshi Oizumi, Akira Inoue, and Naoto Morikawa, “Antiproteinuric effects of renin–angiotensin inhibitors in lung cancer patients receiving bevacizumab,” Cancer Chemotherapy and Pharmacology, 2018. View at Publisher · View at Google Scholar